Behavioral and Cognitive Effects of Anticonvulsant Therapy

There are many potential adverse influences that may impact upon cognitive and behavioral problems of children who have epilepsy. These include inherited tendencies, the underlying epilepsy, associated brain pathology, and psychosocial factors. The role of anticonvulsant therapy in producing adverse neuropsychologic effects has, until recently, been largely ignored. Despite methodologic problems, the Committee on Drugs believes that there is now sufficient information to suggest that antiepileptic therapy has an adverse influence on mental and behavioral functions. Physician awareness of these effects may significantly affect medical practice by influencing the initiation and termination of therapy, the selection of drugs, and approaches to the monitoring of side effects.

EFFECTS OF ANTICONVULSANT THERAPY

Behavioral

The reported incidence of behavioral disturbances in children who are taking phenobarbital has ranged from 9% to 75%. Hyperactivity is the most commonly recognized disturbance; in addition, fussiness, lethargy, disturbed sleep (waking in the middle of the night), irritability, disobedience, stubbornness, and depressive symptoms occur frequently (Table). Barbiturate-induced behavior disturbance is not dose-related and usually appears in the first weeks and months of therapy. Some of the deterioration of fine motor functions and behavior associated with barbiturate administration may be transient; many abnormalities disappear after 1 year.

Phenytoin intoxication is classically associated with the appearance of nystagmus, ataxia, dysarthria, and encephalopathy. Other side effects include extrapyramidal involuntary movements, an increased feeling of tiredness, errors in performance, and, possible, alterations of emotional state.

Adverse behavioral reactions associated with carbamazepine include difficulty in sleeping, agitation, irritability, and emotional lability—possibly occurring more frequently in patients with preexisting central nervous system (CNS) problems. A beneficial effect on mood and behavior has been suggested, possibly because this drug has a chemical resemblance to tricyclic antidepressants. However, because improvements have not been noted universally and because they have occurred primarily in patients who switched from potentially intoxicating drugs (phenobarbital, primidone, and phenytoin), this claim requires additional supporting evidence.

Benzodiazepines are frequently associated with idiosyncratic behavioral disturbances: irritability, aggression, hyperactivity, disobedience, and antisocial activities. The incidence of these effects, especially in the pediatric population, may be as high as 50% with clonazepam therapy.

Sodium valproate acts to increase the plasma concentration of phenobarbital through inhibition of barbiturate metabolism and may result in drowsiness. Volunteers receiving large initial daily doses of valproate appeared to be acutely intoxicated with drowsiness, decreased ability to concentrate, malaise, and speech difficulties. Other investigators found no change in attentiveness, ability to concentration, activity level, disposition, attitude, and interest in a short placebo-controlled study.

Cognitive

Large doses of virtually all anticonvulsant medications can affect mental function. However, during the past decade, reports have been associated with cognitive impairment with therapeutic or supratherapeutic, but not necessarily toxic, anticonvulsant levels. Interpretation of these studies is difficult because (1) many patients were receiving polytherapy, (2) seizure frequency was variable, (3) potentially interfering psychosocial problems were present, and (4) the psychometric tests utilized differed widely among studies.
Attempts to circumvent some of these confounding variables have led to investigations of anticonvulsant effects on cognitive function in nonepileptic adult volunteers. These studies have identified deficits in psychologic test performance with therapeutic and subtherapeutic serum levels of barbiturates and phenytoin and less marked impairments with therapeutic levels of sodium valproate. Thus, these short-term toxicity studies support the theory that there may be a causal relationship between anticonvulsant use and psychologic impairment.

A more difficult question is the extent to which cognitive function in the epileptic patient may be adversely influenced by an anticonvulsant, even though “therapeutic” concentrations are maintained. Several studies have been performed in epileptic patients in order to assess the effect of barbiturates and phenytoin on cognitive function. Thompson and Trimble reported deficits in psychologic test performance in adults with high serum concentrations, although decrements in performance also occurred at lower serum concentrations. These authors noted that documentation of diminished psychologic test performance might be overlooked in standard outpatient interviews because more exacting tests were required. MacLeod et al have shown that phenobarbital selectively impairs short-term memory function with lower test scores associated with higher serum phenobarbital concentrations. In a double-blind, placebo-controlled, randomized febrile seizure study in toddlers, Camfield et al reported that phenobarbital seemed to have an adverse effect on memory concentration tasks despite the fact that no serum levels were in the toxic range. These memory effects were not associated with a difference in the mean IQ scores between children treated with phenobarbital and those treated with placebo. However, declining general comprehension scores in children receiving phenobarbital for longer periods did suggest that treatment for greater than 8 to 12 months might eventually affect IQ scores.

Additional data supporting the proposal that barbiturates affect mental function are derived from reports monitoring changes after drug withdrawal and drug crossover studies. Vining et al, using a double-blind crossover protocol, compared the effects of phenobarbital and valproate in epileptic children. Despite the exclusion of children who had previously been adversely affected by phenobarbital and those who showed obvious behavioral manifestations, the authors reported significantly poorer performances on neuropsychologic tests in patients who were receiving barbiturates. These results were not related to differences in either the frequency of seizures or variations from recommended serum anticonvulsant levels. Furthermore, neither specially designed questionnaires nor physical examinations showed evidence of the psychologic changes readily apparent on validated psychometric testing.

Psychometric studies have also been used to evaluate epileptic patients receiving phenytoin. Dodrill compared patients with high serum phenytoin levels (greater than 30 µg/ml) with a group of patients with lower levels (mean, 17 µg/mL); the toxic group tended to do worse on all measures, especially those involving motor activities. In a double-blind crossover study comparing 4-month trials with phenytoin and carbamazepine therapy, Troupin and Dodrill showed that carbamazepine therapy resulted in fewer errors on tasks involving attention and problem-solving as well as improvement in mood. Recently, Andrewes et al have compared the effects of phenytoin and carba-
mazepine into two groups of patients who were matched for age and IQ and who were similar with respect to seizure type and frequency and duration of treatment. The carbamazepine-treated group performed better on multiple memory tests as well as on a visuomotor task. Studies in children with seizure disorders have also demonstrated that phenobarbital therapy interferes with attentional abilities more than carbamazepine therapy. However, results also suggested that carbamazepine therapy did have some effect on task performance.

Sodium valproate has been less intensively studied. Valproate added to preexisting therapy had no effect on paired associate learning tasks, and its use produced minimal adverse effects in patients performing a series of psychologic tests.

SUMMARY

Behavioral disturbances associated with the use of anticonvulsant therapy may be readily apparent and easily diagnosed. They are most commonly reported with the use of barbiturates and usually include hyperactivity, disturbed sleep, irritability, and emotional lability. But, subtle behavioral disturbances may also adversely affect performance and learning. Behavioral changes resulting from therapy with barbiturates and benzodiazepines tend to be idiosyncratic as opposed to the dose-related affects seen with phenytoin and valproate therapy. Carbamazepine and valproate can affect mood and behavior negatively, but, generally, this occurs less frequently than when several other anticonvulsants are used; this is especially true in patients without CNS damage.

The suspicion that there may be a causal relationship between anticonvulsant therapy and impairment of cognitive skills in nonintoxicated patients is gaining increasing support. Neuropsychologic studies in acutely exposed normal volunteers, studies in epileptic patients receiving monotherapy, and crossover studies between drugs have incriminated barbiturates and hydantoin drugs. Memory/cognitive dysfunction, although affected to a greater extent with higher drug dosages, has been reported with levels within the therapeutic range. Thus, serum drug levels cannot be considered good predictors of which patients will have subtle side effects. Carbamazepine and valproate seem to be relatively free of many adverse neuropsychologic effects, although additional studies need to be performed.

The complete separation of seizure effects from drug effects remains on ongoing goal. Similarly, in comparative studies to date, the issues of whether the differences between the drugs are due to negative effects of one or positive psychotropic effects of the other, or both, are not adequately addressed. In addition, because current physician office procedures do not detect subtle mental impairments, more sensitive techniques are needed to assess potential cognitive and behavioral side effects of medications.

RECOMMENDATIONS

In view of accumulating evidence indicating that anticonvulsant therapy may have detrimental effects on behavior and cognition, the Committee on Drugs makes the following recommendations: (1) Physicians should have an understanding of the natural history of seizure disorders, especially knowledge of when to initiate and when to discontinue medications. For example, febrile seizures may not require treatment, nor may a first, unprovoked seizure. In addition, in a child who remains seizure-free, medication should perhaps be used for no longer than 2 to 4 years. (2) When an antiepileptic medication is required, the physician must consider the specificity of the drug for the seizure type, as well as the drug's potential side effects. Thus, the relative influence of each anticonvulsant agent on behavioral and cognitive function should be considered, along with all other potential adverse effects, when selecting a medication. (3) If anticonvulsant therapy is initiated, the physician should give careful attention to reports from parents and teachers as well as office observations of cognitive function, mood, and behavior during follow-up visits. (4) If significant behavioral or cognitive changes appear and no alternative explanations are readily available, the physician must consider the possibility that anticonvulsant therapy might be responsible and perhaps the dose should be reduced or the medication should be changed. (5) A brief, readily administered, sensitive neuropsychologic screening test capable of detecting subtle intellectual and behavioral side effects should be developed. (6) Finally, the need for the performance of studies designed to evaluate and compare behavioral and cognitive effects of anticonvulsant therapy in children should be recognized and supported.

COMMITTEE ON DRUGS, 1984–1985
Albert W. Pruitt, MD, Chairman
Ralph E. Kauffman, MD
Howard C. Mofenson, MD
Robert J. Roberts, MD
Barry H. Rumack, MD
Harvey S. Singer, MD
Stephen S. Spielberg, MD, PhD
Liaison Representatives
Donald R. Bennett, MD, PhD
Sumner J. Yaffe, MD
Louis Farchione, MD
Martha M. Freeman, MD
Melvin V. Gerbie, MD
Sam A. Licata, MD
Mary Lund Mortensen, MD
AAP Section Liaison
Sanford N. Cohen, MD

REFERENCES

27. Dodrill CB: Diphenylhydantoin serum levels, toxicity, and neuropsychological performance in patients with epilepsy. Epilepsia 1976;16:593–600
Behavioral and Cognitive Effects of Anticonvulsant Therapy

Pediatrics 1985;76;644

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/76/4/644

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
https://shop.aap.org/licensing-permissions/

Reprints
Information about ordering reprints can be found online:
http://classic.pediatrics.aappublications.org/content/reprints

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 1985 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .
Behavioral and Cognitive Effects of Anticonvulsant Therapy

*Pediatrics* 1985;76;644

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/76/4/644